165 related articles for article (PubMed ID: 34879180)
21. Live Macrophage-Delivered Doxorubicin-Loaded Liposomes Effectively Treat Triple-Negative Breast Cancer.
Yang L; Zhang Y; Zhang Y; Xu Y; Li Y; Xie Z; Wang H; Lin Y; Lin Q; Gong T; Sun X; Zhang Z; Zhang L
ACS Nano; 2022 Jun; 16(6):9799-9809. PubMed ID: 35678390
[TBL] [Abstract][Full Text] [Related]
22. Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells.
Ozawa PMM; Alkhilaiwi F; Cavalli IJ; Malheiros D; de Souza Fonseca Ribeiro EM; Cavalli LR
Breast Cancer Res Treat; 2018 Dec; 172(3):713-723. PubMed ID: 30173296
[TBL] [Abstract][Full Text] [Related]
23. Tumor-derived extracellular vesicles for the active targeting and effective treatment of colorectal tumors
Nguyen VD; Kim HY; Choi YH; Park JO; Choi E
Drug Deliv; 2022 Dec; 29(1):2621-2631. PubMed ID: 35941835
[TBL] [Abstract][Full Text] [Related]
24. Biomimetic peptide display from a polymeric nanoparticle surface for targeting and antitumor activity to human triple-negative breast cancer cells.
Bressler EM; Kim J; Shmueli RB; Mirando AC; Bazzazi H; Lee E; Popel AS; Pandey NB; Green JJ
J Biomed Mater Res A; 2018 Jun; 106(6):1753-1764. PubMed ID: 29424479
[TBL] [Abstract][Full Text] [Related]
25. The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors.
Tormo E; Ballester S; Adam-Artigues A; Burgués O; Alonso E; Bermejo B; Menéndez S; Zazo S; Madoz-Gúrpide J; Rovira A; Albanell J; Rojo F; Lluch A; Eroles P
Sci Rep; 2019 Mar; 9(1):5316. PubMed ID: 30926829
[TBL] [Abstract][Full Text] [Related]
26. Macitentan improves antitumor immune responses by inhibiting the secretion of tumor-derived extracellular vesicle PD-L1.
Lee CH; Bae JH; Choe EJ; Park JM; Park SS; Cho HJ; Song BJ; Baek MC
Theranostics; 2022; 12(5):1971-1987. PubMed ID: 35265193
[TBL] [Abstract][Full Text] [Related]
27. Chemotherapy-Induced Extracellular Vesicle miRNAs Promote Breast Cancer Stemness by Targeting
Shen M; Dong C; Ruan X; Yan W; Cao M; Pizzo D; Wu X; Yang L; Liu L; Ren X; Wang SE
Cancer Res; 2019 Jul; 79(14):3608-3621. PubMed ID: 31118200
[TBL] [Abstract][Full Text] [Related]
28. Extracellular vesicles from human liver stem cells inhibit renal cancer stem cell-derived tumor growth in vitro and in vivo.
Brossa A; Fonsato V; Grange C; Tritta S; Tapparo M; Calvetti R; Cedrino M; Fallo S; Gontero P; Camussi G; Bussolati B
Int J Cancer; 2020 Sep; 147(6):1694-1706. PubMed ID: 32064610
[TBL] [Abstract][Full Text] [Related]
29. Covalent conjugation of extracellular vesicles with peptides and nanobodies for targeted therapeutic delivery.
Pham TC; Jayasinghe MK; Pham TT; Yang Y; Wei L; Usman WM; Chen H; Pirisinu M; Gong J; Kim S; Peng B; Wang W; Chan C; Ma V; Nguyen NTH; Kappei D; Nguyen XH; Cho WC; Shi J; Le MTN
J Extracell Vesicles; 2021 Feb; 10(4):e12057. PubMed ID: 33643546
[TBL] [Abstract][Full Text] [Related]
30. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
[TBL] [Abstract][Full Text] [Related]
31. Inhibitory Effect of Oxaliplatin-loaded Engineered Milk Extracellular Vesicles on Tumor Progression.
Go G; Park HJ; Lee JH; Yun CW; Lee SH
Anticancer Res; 2022 Feb; 42(2):857-866. PubMed ID: 35093883
[TBL] [Abstract][Full Text] [Related]
32. TRAIL-modified, doxorubicin-embedded periodic mesoporous organosilica nanoparticles for targeted drug delivery and efficient antitumor immunotherapy.
Feng X; Li F; Zhang L; Liu W; Wang X; Zhu R; Qiao ZA; Yu B; Yu X
Acta Biomater; 2022 Apr; 143():392-405. PubMed ID: 35259519
[TBL] [Abstract][Full Text] [Related]
33.
Zhang Y; Ji W; He L; Chen Y; Ding X; Sun Y; Hu S; Yang H; Huang W; Zhang Y; Liu F; Xia L
Theranostics; 2018; 8(6):1690-1705. PubMed ID: 29556350
[No Abstract] [Full Text] [Related]
34. Trojan horse treatment based on PEG-coated extracellular vesicles to deliver doxorubicin to melanoma
Patras L; Ionescu AE; Munteanu C; Hajdu R; Kosa A; Porfire A; Licarete E; Rauca VF; Sesarman A; Luput L; Bulzu P; Chiroi P; Tranca RA; Meszaros MS; Negrea G; Barbu-Tudoran L; Potara M; Szedlacsek S; Banciu M
Cancer Biol Ther; 2022 Dec; 23(1):1-16. PubMed ID: 34964693
[TBL] [Abstract][Full Text] [Related]
35. Extracellular vesicles produced in B cells deliver tumor suppressor miR-335 to breast cancer cells disrupting oncogenic programming in vitro and in vivo.
Almanza G; Rodvold JJ; Tsui B; Jepsen K; Carter H; Zanetti M
Sci Rep; 2018 Dec; 8(1):17581. PubMed ID: 30514916
[TBL] [Abstract][Full Text] [Related]
36. Functional extracellular vesicles engineered with lipid-grafted hyaluronic acid effectively reverse cancer drug resistance.
Liu J; Ye Z; Xiang M; Chang B; Cui J; Ji T; Zhao L; Li Q; Deng Y; Xu L; Wang G; Wang L; Wang Z
Biomaterials; 2019 Dec; 223():119475. PubMed ID: 31520888
[TBL] [Abstract][Full Text] [Related]
37. Cancer-derived EVs show tropism for tissues at early stage of neoplastic transformation.
Garofalo M; Villa A; Brunialti E; Crescenti D; Dell'Omo G; Kuryk L; Vingiani A; Mazzaferro V; Ciana P
Nanotheranostics; 2021; 5(1):1-7. PubMed ID: 33391971
[TBL] [Abstract][Full Text] [Related]
38. Intercellular adhesion molecule 1 antibody-mediated mesoporous drug delivery system for targeted treatment of triple-negative breast cancer.
Wang M; Liu W; Zhang Y; Dang M; Zhang Y; Tao J; Chen K; Peng X; Teng Z
J Colloid Interface Sci; 2019 Mar; 538():630-637. PubMed ID: 30554096
[TBL] [Abstract][Full Text] [Related]
39. Synergistic Effect of SH003 and Doxorubicin in Triple-negative Breast Cancer.
Woo SM; Kim AJ; Choi YK; Shin YC; Cho SG; Ko SG
Phytother Res; 2016 Nov; 30(11):1817-1823. PubMed ID: 27476488
[TBL] [Abstract][Full Text] [Related]
40. Delivery of miR-424-5p via Extracellular Vesicles Promotes the Apoptosis of MDA-MB-231 TNBC Cells in the Tumor Microenvironment.
Zhou Y; Yamamoto Y; Takeshita F; Yamamoto T; Xiao Z; Ochiya T
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
